Clinical trials: Sclerosis
Pediatric Multiple Sclerosis
Exercise Training in Pediatric-Onset Multiple Sclerosis Patients
Multiple sclerosis is one of the leading causes of disability in young adults. It is known that patients with pediatric onset multiple sclerosis (POMS) experience their first demyelinating attack before the age of 18.
- Trial name
- NCT04660227
- Testing
- Exercise Trainning, Control Group
- Where
- Turkey (Türkiye)
- Volunteers
- 20 people
- Sponsor
- Istanbul University - Cerrahpasa
Familial Amyotrophic Lateral Sclerosis
Treatment of FUS-Related ALS With Betamethasone - The TRANSLATE Study
By doing this study the investigator hopes to learn more about a potential cause of amyotrophic lateral sclerosis (ALS) called "oxidative stress".
- Trial name
- TRANSLATE (NCT03707795)
- Testing
- Betamethasone sodium phosphate/betamethasone acetate (Celestone® Soluspan®), 30 mg IM once a day for four days
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Edward Kasaraskis
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
Cladribine Tablets: Collaborative Study to Evaluate Impact On Central Nervous System Biomarkers in Multiple Sclerosis
The purpose of this study is to better understand the mechanism of action (MoA) of cladribine tablets by exploring the effect on central nervous system (CNS) and blood biomarkers relevant in the relapsing forms of multiple…
- Trial name
- CLOCK-MS (NCT03963375)
- Testing
- Cladribine
- Where
- 5 sites in United States
- Volunteers
- 47 people
- Sponsor
- Gregory Wu
Multiple Sclerosis
The Relationship Between Kinesiophobia, Physical Activity, Balance and Fear of Fall in MS Patients
Multiple sclerosis (MS) is a chronic, inflammatory, demyelinating and neurodegenerative disease of the central nervous system (CNS).
- Trial name
- NCT04183751
- Testing
- scale study
- Where
- Turkey (Türkiye)
- Volunteers
- 40 people
- Sponsor
- Marmara University
Multiple Sclerosis
Scan-Rescan Sub-Study of MS PATHS
The primary objective of this sub-study is to calculate the reproducibility and other technical performance measures of various magnetic resonance imaging (MRI) image analysis algorithms in order to assess their suitability for…
- Trial name
- NCT04123353
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- Biogen
Radiologically Isolated Syndrome, Multiple Sclerosis
Ocrelizumab for Preventing Clinical Multiple Sclerosis in Individuals With Radiologically Isolated Disease.
This is a multicenter, randomized, double-blind, placebo-controlled, Phase 4 study in which eligible patients with RADIOLOGICALLY ISOLATED SYNDROME (RIS) (as defined by meeting 2017 McDonald criteria for DIS) will be randomized…
- Trial name
- CELLO (NCT04877457)
- Testing
- Ocrelizumab
- Where
- 4 sites in United States
- Volunteers
- 3 people
- Sponsor
- Yale University
Multiple Sclerosis, Fatigue
Effects of Vestibular Rehabilitation on MS-related Fatigue: a Randomized Control Trial
The purpose of this study was to test the feasibility and effectiveness of a novel exercise intervention for individuals who live with multiple sclerosis (MS).
- Conditions
- Multiple Sclerosis, Fatigue, Balance, Dizziness
- Trial name
- NCT01216137
- Testing
- Exercise: Vestibular Rehabilitation, Exercise
- Volunteers
- 38 people
- Sponsor
- University of Colorado, Denver
Tetraplegia/Tetraparesis, Amyotrophic Lateral Sclerosis (ALS)
Interfacing With NeuroTechnology to Expand Neural Throughput (INTENT)
The goal of this clinical trial is to evaluate the safety and preliminary efficacy of an implantable device that records and stimulates different areas of the brain to allow adults affected by disabling paralysis (see Eligibility…
- Conditions
- Tetraplegia/Tetraparesis, Amyotrophic Lateral Sclerosis (ALS), Muscular Disorders, Atrophic, Brain Stem Stroke
- Trial name
- INTENT (NCT07521930)
- Testing
- INTENT Neural Interface System
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Johns Hopkins University
Amyotrophic Lateral Sclerosis
Safety and Efficacy of TRO19622 as add-on Therapy to Riluzole Versus Placebo in Treatment of Patients Suffering From ALS
The purpose of the assay is to assess the safety and the efficacy of TRO19622 330 mg QD as add-on therapy to riluzole 50 mg bid in the treatment of patients suffering from ALS, as compared to placebo, assessed by the 18-month…
- Trial name
- MITOTARGET (NCT00868166)
- Testing
- Olesoxime, Riluzole
- Where
- 15 sites in Belgium, France and 3 more
- Volunteers
- 512 people
- Sponsor
- Hoffmann-La Roche
Multiple Sclerosis, Relapsing-Remitting
A Study to Assess the Relative Bioavailability of Different Formulations of GSK2018682, a Sphingosine-1-phosphate Receptor Subtype 1 Agonist, in Healthy Volunteers.
GSK2018682 is a potent and selective agonist for the sphingosine-1- phosphate receptor subtype 1 (S1P1) with the potential to be an effective treatment for multiple sclerosis (MS).
- Trial name
- P1A114919 (NCT01466322)
- Testing
- GSK2018682 CD2 Capsule; GSK2018682 CD3 non-micronised Tablet; GSK2018682 CD3 micronised Tablet; GSK2018682 CD3 non-micronised Tablet in fed state
- Where
- Australia
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Multiple Sclerosis
Combination Therapy With Avonex and BiMonthly High Dose Intravenous Methotrexate in Multiple Sclerosis
The participant will receive weekly intramuscular treatment with AVONEX® (interferon beta 1-a) and bi-monthly high dose intravenous methotrexate with Leucovorin rescue.
- Trial name
- MTX01 (NCT00037102)
- Testing
- interferon beta 1a, methotrexate
- Volunteers
- 16 people
- Sponsor
- MidAmerica Neuroscience Research Foundation at Rowe Neurology Institute
Multiple Sclerosis, Vitamin D Deficiency
Safety and Immunologic Effect of Low Dose Versus High Dose Vitamin D3 in Multiple Sclerosis
The purpose of this study is to determine the safety and the immunologic effects of supplementation with low-dose and high-dose cholecalciferol (vitamin D3) in patients with multiple sclerosis.
- Trial name
- NCT01024777
- Testing
- Cholecalciferol
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Johns Hopkins University
Multiple Sclerosis, Relapsing-Remitting
A Study of Multiple Sclerosis Routine Clinical Practice: Impact on Adherence and Clinical Outcomes of Ofatumumab Treated Patients
This was a retrospective non-interventional study (NIS) of adult (≥18 years) multiple sclerosis (MS) patients on ofatumumab therapy in the United Kingdom (UK) using secondary data.
- Trial name
- NCT06897657
- Where
- United States
- Volunteers
- 155 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis, Neurophysiologic Abnormality
Investigation The Effect of Conventional Vs. Individualized tDCS Intensity to Achieve Uniform E-Fields
Background: Replications of studies employing transcranial direct stimulation (tDCS) shows great variations in physiological and behavioral outcomes.
- Trial name
- NCT05962281
- Testing
- Transcranial direct current stimulation (tDCS)
- Volunteers
- 30 people
- Sponsor
- Koen Cuypers
ALS (Amyotrophic Lateral Sclerosis)
A Study of LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis
The purpose of this study is to evaluate how well LY4256984 is tolerated and what side effects may occur in participants with sporadic amyotrophic lateral sclerosis (ALS).
- Trial name
- NCT07100119
- Testing
- LY4256984
- Where
- 12 sites in Belgium, Canada and 3 more
- Volunteers
- 32 people
- Sponsor
- Eli Lilly and Company
Amyotrophic Lateral Sclerosis, Stroke
Telehealth Implementation of Brain-Computer Interface
Determine if Telehealth intervention can allow/empower a caregiver (who is untrained) to effectively implement and utilize a Brain-Computer Interface for communication with a participant who is "Locked in" following progression…
- Trial name
- NCT05951556
- Testing
- Use of BCI
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Shirley Ryan AbilityLab
Non-relapsing Secondary Progressive Multiple Sclerosis
Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (HERCULES)
Primary Objective: To determine the efficacy of SAR442168 compared to placebo in delaying disability progression in NRSPMS Secondary Objective: To evaluate efficacy of SAR442168 compared to placebo on clinical endpoints, magnetic…
- Trial name
- HERCULES (NCT04411641)
- Testing
- Tolebrutinib
- Where
- 306 sites in United States, Argentina and 29 more
- Volunteers
- 1,131 people
- Sponsor
- Sanofi
Tuberous Sclerosis, Epilepsy
Clinical Trial Data Set Re-use With Statistical Methodologies Tailored for Clinical Trials in Rare Diseases
Tuberous sclerosis complex (TSC), affecting 1 in 6.000 live births, is characterized by the development of multisystem tumors. Seizures are frequent up to 80% of individuals.
- Trial name
- EPISTOPIDEAL (NCT05199402)
- Where
- France
- Volunteers
- 10 people
- Sponsor
- Imagine Institute
Parkinson Disease, Stroke
Smart Wearable Device (gaitQ): Walk Better Project
This study will be underpinned by the new MRC guidelines for developing a complex intervention with a participatory design methodology that uses evidence-based research and behaviour change models alongside COSMIN methodology for…
- Conditions
- Parkinson Disease, Stroke, Multiple Sclerosis, Osteoporosis
- Trial name
- NCT05913219
- Where
- United Kingdom
- Volunteers
- 98 people, healthy volunteers welcome
- Sponsor
- University of Exeter
Amyotrophic Lateral Sclerosis
A Prospective Study to Evaluate the Correlation Between Oculometric Measurements and Clinical Endpoints in ALS Patients
This is a prospective study in a cohort of about 45 patients with ALS participating in the Neurosense PrimeC drug study (NCT05357950).
- Trial name
- NCT05407428
- Testing
- NeuraLight software-based platform
- Where
- Israel
- Volunteers
- 45 people
- Sponsor
- NeuraLight